Teva Q2 revenue $4.2B +7%, non-GAAP EPS $0.61, raises full-year 2024 guidance

TEVA PHARMACEUTICAL INDUSTRIES LTD

2024-Q2 EPS reported -$0.87 revenue$7,983,000,000

Revenue $4.2B (+7% USD, +11% local currency); GAAP loss $0.75/share, non-GAAP EPS $0.61.
Generics grew 16% US, 8% Europe, 22% International; AUSTEDO US revenue $407M (+32%).
Raised 2024 guidance: revenue $16.0-16.4B, non-GAAP EPS $2.30-2.50, adj. EBITDA $4.6-5.0B.
Pipeline: duvakitug top-line now Q4 2024; olanzapine LAI positive Phase 3; SIMLANDI launch.
Free cash flow $324M; $506M tax hit from Israeli Tax Authority settlement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.